Why the study?
Heart failure remains a major cause of cardiac-related morbidity and mortality despite therapeutic advancements, motivating evaluation of newer cardiac myosin activators.
Do cardiac myosin activators improve outcomes and cardiac function in patients with heart failure with reduced ejection fraction?
Do cardiac myosin activators improve outcomes and cardiac function in patients with heart failure with reduced ejection fraction?
Cardiac myosin activators offer a novel mechanism to improve systolic function and reduce heart failure events in HFrEF without the adverse effects typically associated with traditional inotropes.
Cardiac myosin activators merit further study in HF; Level 5 evidence leaves open any role in practice.
Congestive heart failure (HF) remains a major cause of cardiac-related morbidity and mortality, despite major therapeutic advancements. A newer class of medications has recently been developed which targets the root cause of HF, which is reduced myocardial contractility. This article aims to highlight the cardiac myosin activator class of drugs and the trials to date highlighting their effects on HF outcomes.
No takes yet. Share an insight, caveat, or question.
A 2021 study conducted a review in Congestive heart failure with reduced ejection fraction (n=8,256). Omecamtiv mecarbil vs. Placebo was evaluated on Composite of time-to-cardiovascular death or first heart failure event (p=0.03).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: